

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: JKL

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Total (N=254) n (%)
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)	
ANY EVENT				
ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS				
ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS				
ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS				
ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONJUNCTIVITIS	2 (2%)	0 (0%)	0 (0%)	2 (1%)
EYE ALLERGY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE PRURITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE SWELLING	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GLAUCOMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VISION BLURRED	0 (0%)	1 (1%)	1 (1%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: JKL

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>HEPATOBILIARY DISORDERS</b>						
ANY EVENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
<b>IMMUNE SYSTEM DISORDERS</b>						
ANY EVENT	0 (0%)	1 (1%)	1 (1%)	2 (1%)	2 (1%)	
HYPERSENSITIVITY	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)	
SEASONAL ALLERGY	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>						
ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)		
CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)		
EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)		
FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)		
HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)		
JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)		

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: JKL

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)		
<b>METABOLISM AND NUTRITION DISORDERS</b>					
ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)	
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>					
ANY EVENT	5 (6%)	7 (7%)	8 (11%)	20 (8%)	
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
BACK PAIN	1 (1%)	1 (1%)	3 (4%)	5 (2%)	
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)	2 (1%)	
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MYALGIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: JKL

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>					
ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)	
COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
<b>RENAL AND URINARY DISORDERS</b>					
ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	
CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>					
ANY EVENT	2 (2%)	0 (0%)	1 (1%)	3 (1%)	
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: JKL

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>SOCIAL CIRCUMSTANCES</b>						
ANY EVENT	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
ALCOHOL USE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>SURGICAL AND MEDICAL PROCEDURES</b>						
ANY EVENT	2 (2%)	1 (1%)	2 (3%)	5 (2%)		
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)		
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>VASCULAR DISORDERS</b>						
ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)		
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)		
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		

- 
- 1.) Only treatment emergent events related to lipids are displayed.
  - 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: GHI

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
ANY EVENT				
ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS				
ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS				
ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS				
ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONJUNCTIVITIS	2 (2%)	0 (0%)	0 (0%)	2 (1%)
EYE ALLERGY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE PRURITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE SWELLING	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GLAUCOMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VISION BLURRED	0 (0%)	1 (1%)	1 (1%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: GHI

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>HEPATOBILIARY DISORDERS</b>						
ANY EVENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
<b>IMMUNE SYSTEM DISORDERS</b>						
ANY EVENT	0 (0%)	1 (1%)	1 (1%)	2 (1%)	2 (1%)	
HYPERSENSITIVITY	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)	
SEASONAL ALLERGY	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>						
ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)		
CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)		
EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)		
FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)		
HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)		
JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)		

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: GHI

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)		
<b>METABOLISM AND NUTRITION DISORDERS</b>					
ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)	
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>					
ANY EVENT	5 (6%)	7 (7%)	8 (11%)	20 (8%)	
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
BACK PAIN	1 (1%)	1 (1%)	3 (4%)	5 (2%)	
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)	2 (1%)	
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MYALGIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: GHI

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>					
ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)	
COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
<b>RENAL AND URINARY DISORDERS</b>					
ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	
CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>					
ANY EVENT	2 (2%)	0 (0%)	1 (1%)	3 (1%)	
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: XYZ and this is page value 2: GHI

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>SOCIAL CIRCUMSTANCES</b>						
ANY EVENT	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
ALCOHOL USE	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>SURGICAL AND MEDICAL PROCEDURES</b>						
ANY EVENT	2 (2%)	1 (1%)	2 (3%)	5 (2%)		
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)		
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>VASCULAR DISORDERS</b>						
ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)		
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)		
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		

- 
- 1.) Only treatment emergent events related to lipids are displayed.
  - 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: DEF

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Total (N=254) n (%)
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)	
ANY EVENT				
ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS				
ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS				
ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS				
ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONJUNCTIVITIS	2 (2%)	0 (0%)	0 (0%)	2 (1%)
EYE ALLERGY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE PRURITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE SWELLING	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GLAUCOMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VISION BLURRED	0 (0%)	1 (1%)	1 (1%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: DEF

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>HEPATOBILIARY DISORDERS</b>						
ANY EVENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
<b>IMMUNE SYSTEM DISORDERS</b>						
ANY EVENT	0 (0%)	1 (1%)	1 (1%)	2 (1%)	2 (1%)	
HYPERSENSITIVITY	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)	
SEASONAL ALLERGY	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>						
ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)		
CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)		
EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)		
FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)		
HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)		
JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)		

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: DEF

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>METABOLISM AND NUTRITION DISORDERS</b>					
ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)	
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>					
ANY EVENT	5 (6%)	7 (7%)	8 (11%)	20 (8%)	
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
BACK PAIN	1 (1%)	1 (1%)	3 (4%)	5 (2%)	
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)	2 (1%)	
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MYALGIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: DEF

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>					
ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)	
COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
<b>RENAL AND URINARY DISORDERS</b>					
ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	
CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>					
ANY EVENT	2 (2%)	0 (0%)	1 (1%)	3 (1%)	
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: DEF

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>SOCIAL CIRCUMSTANCES</b>						
ANY EVENT	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
ALCOHOL USE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>SURGICAL AND MEDICAL PROCEDURES</b>						
ANY EVENT	2 (2%)	1 (1%)	2 (3%)	5 (2%)		
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)		
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>VASCULAR DISORDERS</b>						
ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)		
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)		
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		

- 
- 1.) Only treatment emergent events related to lipids are displayed.
  - 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: ABC

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
ANY EVENT				
ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS				
ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS				
ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS				
ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONJUNCTIVITIS	2 (2%)	0 (0%)	0 (0%)	2 (1%)
EYE ALLERGY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE PRURITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE SWELLING	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GLAUCOMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VISION BLURRED	0 (0%)	1 (1%)	1 (1%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: ABC

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>HEPATOBILIARY DISORDERS</b>						
ANY EVENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)	
<b>IMMUNE SYSTEM DISORDERS</b>						
ANY EVENT	0 (0%)	1 (1%)	1 (1%)	2 (1%)	2 (1%)	
HYPERSENSITIVITY	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)	
SEASONAL ALLERGY	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>						
ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)		
CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)		
EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)		
FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)		
HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)		
JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)		

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: ABC

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>METABOLISM AND NUTRITION DISORDERS</b>					
ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)	
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>					
ANY EVENT	5 (6%)	7 (7%)	8 (11%)	20 (8%)	
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
BACK PAIN	1 (1%)	1 (1%)	3 (4%)	5 (2%)	
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)	2 (1%)	
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)	2 (1%)	
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MYALGIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: ABC

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
		Low Dose (N=96) n (%)			
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>					
ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)	
COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
<b>RENAL AND URINARY DISORDERS</b>					
ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	
CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	
MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
<b>REPRODUCTIVE SYSTEM AND BREAST DISORDERS</b>					
ANY EVENT	2 (2%)	0 (0%)	1 (1%)	3 (1%)	
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)	
PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 10: Summary of Treatment Emergent Adverse Events

This is page value 1: UVW and this is page value 2: ABC

Body System or Organ Class Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline		Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)	
		Low Dose (N=96) n (%)	High Dose (N=72) n (%)			
<b>SOCIAL CIRCUMSTANCES</b>						
ANY EVENT	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
ALCOHOL USE	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)	
<b>SURGICAL AND MEDICAL PROCEDURES</b>						
ANY EVENT	2 (2%)	1 (1%)	2 (3%)	5 (2%)		
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)		
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)		
<b>VASCULAR DISORDERS</b>						
ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)		
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)		
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)		
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)		
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)		
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)		

- 
- 1.) Only treatment emergent events related to lipids are displayed.
  - 2.) Subjects are only counted once within each body system and preferred term.